• Antimalarial


  • 8-aminoquinoline, related to 4- aminoquinoline


  • · P. vivax malaria treatment


  • Concomitant administration of quinacrine

  • Concomitant administration of poitentially hemolytic or bone marrow suppressive medications


  • Pregnancy category C

  • Patients suffering from P. vivax malaria should receive chloroquine which quickly destroys erythrocytic parasites and terminates paroxysm.  Primaquine destroys exoerythrocytic parasites.

  • Anemia or methemoglobinemia with large doses

  • Do not exceed recommended doses

  • Perform routine blood counts and hemoglobin determinations during therapy

  • Report signs of “chinconism” (tinnitis, headache, nausea, vision changes)

  • Dosages expressed in form of Primaquine base:

    • Primaquine Phosphate 26.3mg = Primaquine base 15mg

Adverse Reactions (Side Effects):

  • Gastrointestinal: nausea, vomiting, epigastric distress, cramping

  • Hematologic: leukopenia, hemolytic anmeia in patient with G-6-PD deficiency


  • Administered orally

  • Dosages listed in Primaquine base strength (PB)

  • Begin therapy during last two weeks of, or following a course of, suppression with Chloroquine or comparable medication

  • Malaria treatment:

    • Adult: 315mg PB every day for 14 days

    • Child: (dosed per weight): 0.3mg/kg/day PB every day for 14 days

Back to Medical Corps Pharmacy Page